Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 890 participants.

Also called NCT07201688

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 890 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07201688
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07201688. Randomized; triple masking; primary purpose treatment. Start 2025-11-30 (actual); primary completion 2027-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
Acronym
TRACE-LATE
Condition
Acute Ischemic Stroke
Intervention (Drug)
rhTNK-tPA
Intervention (Drug)
Placebo
Lead sponsor
CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07201688
Content hash
f948ce09702b4ca008304e9db2f917d5a6a004f3a9d4ac474a033eefacd46a94